Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
0 hedge funds and large institutions have $0 invested in Biocept, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 13 closing their positions.
100% less funds holding
Funds holding: 13 → 0 (-13)
100% less capital invested
Capital invested by funds: $218K → $0 (-$218K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 13
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$147K |
| 2 |
VF
Virtu Financial
New York
|
-$17K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$15.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
BIOC Hedge Fund Activity: Q4 2023 in Review
0 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q4 2023, worth a combined $0 — down 100% from $218K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BIOC and 0 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Alyeska Investment Group, exiting entirely with an estimated $147K sold.
- 0 institutional investors held Biocept, Inc. (BIOC) as of Q4 2023, down from 13 in Q3 2023.
- Funds reported $0 of Biocept, Inc. stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Biocept, Inc. positions in Q4 2023 and 13 closed out, a net change of -13 holders.
- The largest Biocept, Inc. seller in Q4 2023 was Alyeska Investment Group, an estimated $147K sold.
Based on aggregated 13F filings for Q4 2023.